PROTOKOLwiki
COMPOUNDS / ADAPTOGEN / HHZ
ADAPTOGEN

HHZ

LOW RISK
BEST FOR:Cognition●●●●○○○○○○4/10
HHZ · HYDROLEA ZEYLANICA EXTRACT · HYDROLEA ZEYLANICA HYDROALCOHOLIC EXTRACT · H. ZEYLANICA LEAF EXTRACT
NootropicAntioxidantAnticholinesterasePlant ExtractDiabetic EncephalopathyTraditional Medicine

Hydroalcoholic leaf extract of Hydrolea zeylanica with antioxidant, anti-inflammatory, and cholinesterase-inhibiting properties studied for diabetic cognitive impairment.

ROUTE / DOSAGE
LOW2000mg
STANDARD3000-4000mg
HIGH5000mg+
Note: Dosing extrapolated from rat studies at 300-400 mg/kg using standard conversion; human dosing not established
CYCLE
Daily up to 4 weeks continuous
BIOAVAILABILITY
Unknown oral bioavailability not characterized
ACTIVE DURATION
6-8h (subjective)
STORAGE
Store in airtight container away from light and moisture at room temperature
HALF-LIFE
Unknown (plasma)
DURATION BREAKDOWN
Total6-8 hours
Onset1-2 hours
Come up1-2 hours
Peak2-4 hours
Offset2-3 hours
After effects4-8 hours
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
7 documented
Improved learning and memory in diabetic models
Reduced serum glucose and elevated insulin
Inhibition of acetylcholinesterase and butyrylcholinesterase
Reduced oxidative stress markers (MDA, SOD, CAT, GSH)
Decreased pro-inflammatory cytokines (TNF-α, IL-6, hs-CRP)
Inhibition of β-secretase (BACE1, BACE2) activity
Preserved cortical histological architecture
§ 02 — RISKS
No human safety or pharmacokinetic data exists; all evidence is from a single rat study
Optimal human dosing is unknown and extrapolated from animal models
Potential drug interactions with cholinesterase inhibitors or antidiabetic medications not studied
Long-term safety profile uncharacterized
Effects in non-diabetic cognitive impairment are untested
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

A single rat study demonstrated that oral HHZ at 300 and 400 mg/kg for 4 weeks significantly improved learning and memory in HFD/STZ-induced diabetic encephalopathy, reducing serum glucose and elevating insulin. HHZ showed dose-dependent inhibition of AChE and BChE in vitro, and reduced BACE1/BACE2 activity in brain tissue. Antioxidant and anti-inflammatory markers were significantly improved, and cortical histology was preserved. HPLC analysis confirmed flavonoid and nutrient content. Evidence is limited to one preclinical study; no human trials, pharmacokinetic data, or safety pharmacology in humans exist. The cognitive benefits observed may not translate to non-diabetic populations.

§ 06 — SOURCES
[1]
PubMed PMID 36387425
pubmed.ncbi.nlm.nih.gov ↗
[2]
PubMed PMID 36932862
pubmed.ncbi.nlm.nih.gov ↗
[3]
PubMed PMID 36430523
pubmed.ncbi.nlm.nih.gov ↗
[4]
PubMed PMID 34465003
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT